Article
Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.
Blood - 18 May 2017
Ennishi Daisuke, Mottok Anja, Ben-Neriah Susana, Shulha Hennady P, Farinha Pedro, Chan Fong Chun, Meissner Barbara, Boyle Merrill, Hother Christoffer, Kridel Robert, Lai Daniel, Saberi Saeed, Bashashati Ali, Shah Sohrab P, Morin Ryan D, Marra Marco A, Savage Kerry J, Sehn Laurie H, Steidl Christian, Connors Joseph M, Gascoyne Randy D, Scott David W
Abstract excerpt
The clinical significance of MYC and BCL2 genetic alterations in diffuse large B-cell lymphoma (DLBCL), apart from translocations, has not been comprehensively investigated using high-resolution genetic assays. In this study, we profiled MYC and BCL2 genetic alterations using next-generation sequencing and high-resolution SNP array in 347 de novo DLBCL cases treated with R-CHOP (rituximab, cyclophosphamide,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
